Standout Papers
Citation Impact
Citing Papers
2014
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
2017
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Comprehensive computational design of ordered peptide macrocycles
2017 StandoutScienceNobel
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
2017
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
2014
The use of mRNA display to select high-affinity protein-binding peptides
2001 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Hot-spot mimicry of a cytokine receptor by a small molecule
2006
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
2017 Science
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Subtilases: The superfamily of subtilisin-like serine proteases
1997
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Tumor-targeting peptides from combinatorial libraries
2016
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
2007 StandoutNature
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Selection and evolution of enzymes from a partially randomized non-catalytic scaffold
2007 StandoutNatureNobel
Combination cancer immunotherapy and new immunomodulatory targets
2015
Combinatorial and computational challenges for biocatalyst design
2001 StandoutNatureNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Dual Detection of Fungal Infections in Drosophila via Recognition of Glucans and Sensing of Virulence Factors
2006 StandoutNobel
Computational Enzyme Design
2013 StandoutNobel
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
2001 Standout
The Radical SAM Superfamily
2008
Aminomutases: mechanistic diversity, biotechnological applications and future perspectives
2011 StandoutNobel
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses
2000
T Cell Dysfunction in Cancer
2018
Expanding the Enzyme Universe: Accessing Non‐Natural Reactions by Mechanism‐Guided Directed Evolution
2015 StandoutNobel
Catalytic antibodies: hapten design strategies and screening methods
2004
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
2015
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Lung cancer: current therapies and new targeted treatments
2016 Standout
In vitro selection of nucleic acids and proteins: what are we learning?
1999
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Reconstructing the diversification of subtilisins in the pathogenic fungus Metarhizium anisopliae
2003
Adenosyl Radical: Reagent and Catalyst in Enzyme Reactions
2010
G Protein-coupled Receptor Kinase 5 Regulates β1-Adrenergic Receptor Association with PSD-95
2002 StandoutNobel
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Enzymatic functionalization of carbon–hydrogen bonds
2010 StandoutNobel
Mechanism‐Inspired Engineering of Phenylalanine Aminomutase for Enhanced β‐Regioselective Asymmetric Amination of Cinnamates
2011 StandoutNobel
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
2016
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
2017
Cold Adaptation of a Mesophilic Subtilisin-like Protease by Laboratory Evolution
2000 StandoutNobel
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Engineering new functions and altering existing functions
1996
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Phage-display technology – finding a needle in a vast molecular haystack
1999
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry
2011
Search and Discovery Strategies for Biotechnology: the Paradigm Shift
2000
Dynamical Contributions to Enzyme Catalysis: Critical Tests of A Popular Hypothesis
2006 StandoutNobel
Generation of New Enzymes via Covalent Modification of Existing Proteins
2001
RadicalS-Adenosylmethionine Enzymes
2014
Computational method to reduce the search space for directed protein evolution
2001 StandoutNobel
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Molecular and Biotechnological Aspects of Microbial Proteases
1998 Standout
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
2013
Applications of small-molecule combinatorial chemistry to drug discovery
1996
The Organocatalytic Approach to Enantiopure 2H‐ and 3H‐Pyrroles: Inhibitors of the Hedgehog Signaling Pathway
2016 StandoutNobel
Mutational Analysis of Backbone Hydrogen Bonds in Staphylococcal Nuclease
1997
Apparent NAC Effect in Chorismate Mutase Reflects Electrostatic Transition State Stabilization
2003 StandoutNobel
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
S-Adenosylmethionine: A Wolf in Sheep's Clothing, or a Rich Man's Adenosylcobalamin?
2003
Copper-Catalyzed Synthesis of Mixed Alkyl Aryl Phosphonates
2014 StandoutNobel
Drug Discovery: A Historical Perspective
2000 StandoutScience
Structure-Based Design of β-Site APP Cleaving Enzyme 1 (BACE1) Inhibitors for the Treatment of Alzheimer’s Disease
2013
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand
2005
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016
Mechanistic Diversity of Cytokine Receptor Signaling Across Cell Membranes
2004
Molecular breeding: The natural approach to protein design
2001
Toxicities of Immunotherapy for the Practitioner
2015
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Enzyme Redesign
2001
Binding Energy and Catalysis: The Implications for Transition-State Analogs and Catalytic Antibodies
1997
Electrostatic Basis for Enzyme Catalysis
2006 StandoutNobel
Chemomimetic Biocatalysis: Exploiting the Synthetic Potential of Cofactor-Dependent Enzymes To Create New Catalysts
2015 StandoutNobel
DNA-Based Asymmetric Catalysis: Sequence-Dependent Rate Acceleration and Enantioselectivity
2008 StandoutNobel
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
Neoantigens in cancer immunotherapy
2015 StandoutScience
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
2016
Dynamic Control of Chiral Space in a Catalytic Asymmetric Reaction Using a Molecular Motor
2011 StandoutScienceNobel
Ghrelin is a growth-hormone-releasing acylated peptide from stomach
1999 StandoutNature
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins
1997
Works of Marcus Ballinger being referenced
Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display
1998
An organic radical in the lysine 2,3-aminomutase reaction
1992
Designing Subtilisin BPN' To Cleave Substrates Containing Dibasic Residues
1995
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Semirational design of a potent, artificial agonist of fibroblast growth factor receptors
1999
Structure of a substrate radical intermediate in the reaction of lysine 2,3-aminomutase
1992
Furilisin: A Variant of Subtilisin BPN‘ Engineered for Cleaving Tribasic Substrates
1996
Association of PD-L2 expression in human tumors with atezolizumab activity.
2016
Differential binding energy: a detailed evaluation of the influence of hydrogen-bonding and hydrophobic groups on the inhibition of thermolysin by phosphorus-containing inhibitors
1991
Pulsed electron paramagnetic resonance studies of the lysine 2,3-aminomutase substrate radical: Evidence for participation of pyridoxal 5'-phosphate in a radical rearrangement
1995
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
2013
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
2017
Aminoethylenes: A Tetrahedral Intermediate Isostere Yielding Potent Inhibitors of the Aspartyl Protease BACE-1
2006
Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis
1998
Fmoc-based synthesis of glycolate ester peptides for the assembly of de novo designed multimeric proteins using subtiligase
1996
Lysine 2,3-Aminomutase: Rapid Mix−Freeze−Quench Electron Paramagnetic Resonance Studies Establishing the Kinetic Competence of a Substrate-Based Radical Intermediate
1996
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).
2015